‘Game-changer’ GLP-1s could fix America’s obesity crisis—but 2 inequalities stand in the way

A potential "game-changer" in the world of obesity treatment, GLP-1 drugs like Ozempic, Wegovy, and Zepbound have transformed the approach to managing obesity, moving treatment from reactive measures like gastric bypass and surgery to proactive weight management. According to Robin Wenzel, head of Wells Fargo Industry Insights, this shift in treatment "upstream" could have significant economic implications, potentially reducing the need for expensive surgical interventions.

The data supports this assertion, as GLP-1 usage increased more than 140% between 2022 and 2024, while bariatric surgery volumes fell by 34.1% over the same period. Additionally, cardiovascular outcomes may be a major area of impact, as a 2026 JAMA Surgery analysis found semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults without diabetes.

Obesity therapies now account for approximately 25% of pharma's forecast late-stage drug pipeline value, surpassing oncology for the first time in 16 years. Emerging research also suggests GLP-1s may help reduce substance abuse, including alcohol use disorder. Despite the clinical promise, the cost of these drugs remains a significant barrier.

With list prices as high as $1,000 to $1,300 a month for Wegovy and Ozempic, and both drugs remaining under patent, competition is limited. The Congressional Budget Office estimates that broadly covering anti-obesity medications under Medicare would add about $35 billion to federal spending between 2026 and 2034, with near-term costs of $5,600 per user in 2026 versus estimated savings of just $50 per user.

This creates a "patience tax," where patients and payers must absorb years of costs before seeing the benefits. The arrival of price relief for Novo Nordisk's Wegovy and Ozempic, however, could help alleviate some of these concerns.